Form 4: Rhythm Pharmaceuticals Director Edward Mathers Granted New Equity Awards

Rhythm Pharmaceuticals, Inc. Director Edward T. Mathers has been granted new stock options and restricted stock units as part of his compensation, aligning his interests with shareholders.

Summary

• Edward T. Mathers, a Director of RHYTHM PHARMACEUTICALS, INC. (RYTM), was granted new equity awards on June 24, 2025.
• The awards include 7,037 stock options with an exercise price of $63.66 per share, expiring on June 23, 2035.
• The stock options will fully vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, subject to continued service.
• Additionally, Mr. Mathers received 4,712 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The RSUs will fully vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, subject to continued service, and have no expiration date.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity awards, which is a standard and generally favorable practice.

Positives

• The granting of equity awards to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The awards represent a commitment to retaining key board members and their expertise.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity compensation.

Industry Context

The granting of stock options and restricted stock units is a standard practice in the biotechnology and pharmaceutical industry for compensating directors and executives, aiming to align their incentives with the company's long-term success and shareholder value creation. This is a routine compensation event for a director.

Comparison to Industry Standards

• The structure of equity compensation, including stock options and restricted stock units with vesting schedules tied to continued service, is a common practice across the biotech and broader corporate sectors.
• While specific award sizes vary by company size, performance, and individual role, the use of these instruments for director compensation is consistent with industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards are intended to align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options and restricted stock units will vest according to their specified schedules, contingent on the director's continued service.

Key Dates

Keywords

SEC Form 4, Rhythm Pharmaceuticals, RYTM, Edward T. Mathers, Director, Stock Options, Restricted Stock Units, Equity Awards, Insider Transaction, Compensation, Corporate Governance